Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast
This article was originally published in The Pink Sheet Daily
With a foundation established in oncology, Celgene is targeting new areas for growth; apremilast, for psoriasis and psoriatic arthritis, is key to the effort.
You may also be interested in...
A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.
Celgene will buy Receptos for $7.2 billion, gaining the late-stage drug ozanimod in development for multiple sclerosis and ulcerative colitis. With the addition of ozanimod, the company will have three late-stage drugs in its inflammation and immunology portfolio.